Follow
Promising news, vivax is the dominant plasmodium species in many regions - including Brazil.
"Here, Hou et al. report encouraging clinical trial results testing the safety and efficacy of two vaccine candidates, both based on the P. vivax Duffy-binding protein region II (PvDBPII). One of the vaccine candidates, an adjuvanted PvDBPII protein vaccine, elicited the strongest antibody responses, particularly when delivered in a delayed dosing regimen."
